For nearly 25 years, GlaxoSmithKline’s (“GSK”) Zofran (ondansetron) has been used to alleviate nausea and vomiting in cancer patients enduring chemotherapy or radiation therapy—however the FDA has never approved the anti-nausea medicine for use in pregnant women. Unfortunately, GSK’s alleged “off label” marketing of the drug to expectant mothers may have cost one family their child’s life.
In a Zofran (ondansetron) lawsuit filed in the Northern District of Ohio, a couple is claiming GSK is responsible for their daughter’s death after the baby was born with heart defects, passing away just three days after her birth. The couple is alleging that the drugmaker fraudulently promoted Zofran (ondansetron) while failing to warn about the risks of congenital heart defects.
Attorneys at G&E represent dozens of mothers and families with similar claims and have a leading role in the current Zofran MDL litigation. If you or a loved one took Zofran (ondansetron) for morning sickness during your first trimester and your baby was born with a congenital heart defect or cleft palate, please contact us at 877-978-0169 for a confidential evaluation of your potential claim.